Medicines access
An access strategy needs to hold together from the first request to the final handover. IAE connects the route, the responsibilities and the practical arrangements before a commitment becomes a delivery problem.
Discuss access strategy
The decision
A request reaches medical affairs. A trial approaches its final visit. A programme is ready to enter another country. Each starts an access conversation; each brings a different set of decisions. The route, company policy, local requirements, continuing supply and responsibilities for care need to be assessed together.
Treating the request as a supply question can leave the wider programme unresolved. Treating it only as a regulatory question can miss the work that sites, partners and patients will depend on.
IAE gives the commissioning team an independent view of the options, the conditions attached to them and the work required to put the agreed approach into practice.
A connected assessment, a clear recommendation and support for the work that follows.
Assess the proposed activity, relevant jurisdictions and route options. Bring early and expanded access, named-patient or compassionate-use arrangements and company policy into a decision that reflects the actual programme.
Connect country assessment, request handling, eligibility responsibilities, site readiness, supply, safety reporting and communications. Define the interfaces that sponsors, providers and healthcare teams need to operate.
Work through post-trial access, country additions, provider changes and programme closure. Set the decisions, dependencies and readiness conditions before communicating the transition.
The exact deliverables are agreed for the assignment. Typical outputs include:
Options, recommendations, assumptions and the questions requiring local or specialist resolution.
An operating model, responsibilities, governance and a sequenced implementation plan.
Continuity arrangements, handovers, readiness criteria and decisions for the responsible parties.
Access planning also needs an evidence purpose and a delivery model. Where these are part of the assignment, IAE brings the relevant workstreams into the same plan.
Clinical suitability and individual access decisions remain with the treating team and responsible company or programme. IAE provides advisory and implementation support to organisations; it does not arrange treatment access for individuals. Find general information and official routes
Share the situation, your intended outcome and any timing that matters. You do not need a complete brief to begin.
Discuss access strategyScope, responsibilities and fees are agreed before work begins.
